Banner - NPPA Connect
|Articles|May 30, 2017

Edge Systems changes name to The HydraFacial Company

Edge Systems, known for its patented HydraFacial and Perk skincare technologies, has changed its name to The Hydrafacial Company, according to a company press release.

Edge Systems, known for its patented HydraFacial and Perk skincare technologies, has changed its name to The Hydrafacial Company, according to a company press release.

Established in 1997, the Signal Hill, Calif.-based company has products in more than 75 countries. Healthcare-focused private equity firms Linden Capital Partners and DW Healthcare Partner jointly acquired Edge Systems in December 2016 with a vision to invest in the global expansion of the HydraFacial brand, according to the release.

Clint Carnell, chief executive officer of The HydraFacial Company, said in the release that near-term plans are to grow the HydraFacial brand, with patient awareness and physician support.

There’s also a “refreshed” look to the HydraFacial brand, according to Rosemarie Holcomb, director of marketing for The HydraFacial Company. The technology, Holcomb tells Dermatology Times, will remain consistent.

“Doctors should expect to have more patients walking through their doors asking for the treatments by name,” Holcomb says. “HydraFacial and Perk are the two brands currently under The HydraFacial Company umbrella. We plan to incorporate more award-winning technologies under The HydraFacial Company in the future.”

A priority is global consumer outreach, according to Holcomb.

“Our new brand language is concise and clear so potential new patients can understand the technology and importance of the results,” she says.  


Related to this article

Day 3 Recap: Fall Clinical 2026
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
Day 2 Recap: Fall Clinical 2026
The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results, along with 3-year nemolizumab findings, upadacitinib switch data, and expert guidance on choosing a biologic in atopic dermatitis.